家族性高胆固醇血症儿童期启动降脂治疗与长期结局:SAFEHEART研究
SAFEHEART前瞻性队列纳入348例基因确诊的杂合子FH儿童/青少年、165例非FH儿童亲属和288例FH父母,中位随访12.4年。儿童期启动降脂治疗使LDL-C降幅达47.4%,至39岁时心血管事件率仅0.3%,显著低于父母的5.2%,支持FH作为儿科疾病早期筛查治疗。
要点
- FH儿童青少年期启动降脂治疗可显著降低累积LDL-C负荷
- 儿童期治疗使LDL-C水平接近非FH个体
- 早治疗与年轻FH患者心血管风险降低相关
核心结论
- 儿童/青少年期启动降脂治疗较成年后治疗可降低FH患者累积LDL-C负荷,并使LDL-C接近非FH个体水平,与年轻FH患者心血管风险降低相关。
研究设计与样本
- 观察性前瞻性队列研究(SAFEHEART),纳入348例基因确诊的杂合子FH儿童/青少年(FH-Ch)、165例非FH儿童/青少年亲属(non-FH-Ch)和288例FH父母(FH-P),中位随访12.4年(IQR 9.6-15.3)。
主要发现
- 随访时84.5% FH-Ch、4.2% non-FH-Ch和95.1% FH-P接受降脂药物治疗。
- FH-Ch启动治疗中位年龄14.5岁,FH-P为36.1岁。
- FH-Ch最新治疗后LDL-C为3.00 mmol/L(中位变化-2.60 mmol/L,-47.4%),FH-P为2.44 mmol/L(-4.72 mmol/L,-67.6%),non-FH-Ch为2.72 mmol/L。
- 至39岁时,non-FH-Ch、FH-Ch和FH-P的心血管事件率分别为0.0%、0.3%和5.2%。
临床怎么用
- 支持将FH视为儿科疾病,需在生命早期进行检测并启动降脂治疗以降低累积LDL-C负荷和心血管风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) leads to life-long exposure to high low-density lipoprotein cholesterol (LDL-C) and increased risk of premature atherosclerotic cardiovascular disease. Evidence supporting initiation of cholesterol-lowering medication (CLM) in childhood to lower this cumulative cholesterol burden and cardiovascular sequelae is sparse. This study assessed the long-term impact of contemporary management of FH on LDL-C and cardiovascular events. METHODS: Observational prospective cohort study (SAFEHEART) including children/adolescents (age <18 years) with genetically confirmed heterozygous FH (FH-Ch), their non-affected children and adolescents' relatives (non-FH-Ch), and FH parents (FH-P). Impact of CLM, LDL-C burden, and cardiovascular events were assessed. RESULTS: Overall, 348 FH-Ch, 165 non-FH-Ch and 288 FH-P were included (49.8% female; median untreated LDL-C: 5.46, 2.63, and 7.19 mmol/L, respectively). Median follow-up was 12.4 years (interquartile range 9.6-15.3). At follow-up, 84.5% FH-Ch, 4.2% non-FH-Ch, and 95.1% FH-P were receiving CLM. FH-Ch started therapy at a median age of 14.5, vs. 36.1 years in their FH-P. Latest on-treatment LDL-C was 3.00 mmol/L in FH-Ch (median change: -2.60 mmol/L, -47.4%) and 2.44 mmol/L in FH-P (-4.72 mmol/L, -67.6%); LDL-C among non-FH-Ch (not on CLM) was 2.72 mmol/L. By age 30-40 years, median LDL-C burden over life was 5909.0 and 10 206.8 mg/dL*years among FH-Ch and FH-P, respectively. By age 39 years, rate of cardiovascular events was 0.0%, 0.3% and 5.2% among non-FH-Ch, FH-Ch, and FH-P, respectively. CONCLUSIONS: Treatment of FH from childhood/adolescence reduces the cumulative LDL-C burden compared with later onset treatment from adulthood in affected parents and permits attainment of LDL-C levels close to non-FH individuals; this finding was associated with the observation of a reduction in the cardiovascular risk of young FH patients. These findings support FH as a paediatric condition requiring early-life detection and treatment. STUDY REGISTRATION NUMBER: ClinicalTrials.gov, NCT02693548.
引用
- Vallejo-Vaz AJ, Arroyo-Olivares R, Alonso R, et al. Cholesterol-lowering therapy from childhood/adolescence and long-term outcomes in familial hypercholesterolaemia: the SAFEHEART study. Eur Heart J. 2026. PMID: 42290618. doi:10.1093/eurheartj/ehag349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。